40 Appendix 2, Regulation (EU) 2019/1390

In forcesince 31 Jul 2019
1.

This in vitro Estrogen Receptor (ERα) saturation and competitive binding assay uses full length human receptor ERα (hrERα) that is produced in and isolated from baculovirus-infected insect cells. The protocol, developed by Freyberger and Wilson, underwent an international multi-laboratory validation study (2) which has demonstrated its relevance and reliability for the intended purpose of the assay.

2.

This assay is a screening procedure for identifying substances that can bind to the full length hrERα. It is used to determine the ability of a test chemical to compete with 17β-estradiol for binding to hrERα. Quantitative assay results may include the IC50 (a measure of the concentration of test chemical needed to displace half of the [3H]-17β-estradiol from the hrERα) and the relative binding affinities of test chemicals for the hrERα compared to 17β-estradiol. For chemical screening purposes, acceptable qualitative assay results may include classifications of test chemicals as either hrERα binders, non-binders, or equivocal based upon criteria described for the binding curves.

3.

The assay uses a radioactive ligand that requires a radioactive materials license for the laboratory. All procedures with radioisotopes and hazardous chemicals should follow the regulations and procedures as described by national legislation.

4.

The “GENERAL INTRODUCTION” and “hrER BINDING ASSAY COMPONENTS” should be read before using this assay for regulatory purposes. Definitions and abbreviations used in this TG are described in Appendix 1.

5.

The hrERα binding assay measures the ability of a radiolabelled ligand ([3H]17β-estradiol) to bind with the ER in the presence of increasing concentrations of a test chemical (i.e. competitor). Test chemicals that possess a high affinity for the ER compete with the radiolabelled ligand at a lower concentration as compared with those chemicals with lower affinity for the receptor.

6.

This assay consists of two major components: a saturation binding experiment to characterise receptor-ligand interaction parameters, followed by a competitive binding experiment that characterises the competition between a test chemical and a radiolabelled ligand for binding to the ER.

7.

The purpose of the saturation binding experiment is to characterise a particular batch of receptors for binding affinity and number in preparation for the competitive binding experiment. The saturation binding experiment measures, under equilibrium conditions, the affinity of a fixed concentration of the estrogen receptor for its natural ligand (represented by the dissociation constant, Kd), and the concentration of active receptor sites (Bmax).

8.

The competitive binding experiment measures the affinity of a substance to compete with [3H]17β-estradiol for binding to the ER. The affinity is quantified by the concentration of test chemical that, at equilibrium, inhibits 50 % of the specific binding of the [3H]17β-estradiol (termed the “inhibitory concentration 50 %” or IC50). This can also be evaluated using the relative binding affinity (RBA, relative to the IC50 of estradiol measured separately in the same run). The competitive binding experiment measures the binding of [3H]17β-estradiol at a fixed concentration in the presence of a wide range (eight orders of magnitude) of test chemical concentrations. The data are then fit, where possible, to a form of the Hill equation (Hill, 1910) that describes the displacement of the radioligand by a one-site competitive binder. The extent of displacement of the radiolabelled estradiol at equilibrium is used to characterise the test chemical as a binder, non-binder, or generating an equivocal response.

9.

Prior to routinely conducting the saturation and competitive binding assays, each new batch of hrERα should be shown to be performing correctly in the laboratory in which it will be used. A two-step process should be used to demonstrate performance. These steps are the following:

Conduct a saturation [3H]-17β-estradiol binding assay to demonstrate hrERα specificity and saturation. Nonlinear regression analysis of these data (e.g. BioSoft; McPherson, 1985; Motulsky, 1995) and the subsequent Scatchard plot should document hrERα binding affinity of the [3H]-17β-estradiol (Kd) and the number of receptors (Bmax) for each batch of hrERα.

Conduct a competitive binding assay using the control substances (reference estrogen (17β-estradiol)), a weak binder (e.g. norethynodrel or norethindrone), and a non-binder (octyltriethoxysilane, OTES). Each laboratory should establish an historical database to document the consistency of IC50 and other relevant values for the reference estrogen and weak binder among experiments and different batches of hrERα. The parameters of the competitive binding curves for the control substances should be within the limits of the 95 %confidence interval (see Table 1) that were developed using data from laboratories that participated in the validation study for this assay (2).

[Mean (n) ± Standard Deviation (SD) were calculated using curve fit parameter estimates (4-parameter Hill Equation) for control runs conducted in four laboratories during the validation study (see Annex N of Reference 2).] [The 95 % confidence intervals are provided as a guide for acceptability criteria.] [Testing of norethindrone was optional for Subtask 4 during validation study (see Reference 2, see Subtask 4). Thus, the mean ± SD (n) were calculated using curve fit estimates (4-parameter Hill equation) for control runs conducted in two laboratories. The range for the IC50 will be dependent upon the Kd of the receptor preparation and concentration of radiolabelled ligand used within each laboratory. Appropriate adjustment for the range of the IC50 based upon the conditions used to conduct the assay will be acceptable.]

Substance | Parameter | Mean | Standard Deviation (n) | 95 % Confidence Intervals

Lower Limit | Upper Limit

17β-estradiol | Top (%) | 100,44 | 10,84 (67) | 97,8 | 103,1

Bottom (%) | 0,29 | 1,25 (67) | -0,01 | 0,60

Hill Slope | -1,06 | 0,20 (67) | -1,11 | -1,02

LogIC50 (M) | -8,92 | 0,18 (67) | -8,97 | -8,88

Norethynodrel | Top (%) | 99,42 | 8,90 (68) | 97,27 | 101,60

Bottom (%) | 2,02 | 3,42 (68) | 1,19 | 2,84

Hill Slope | -1,01 | 0,38 (68) | -1,10 | -0,92

Log IC50 (M) | -6,39 | 0,27 (68) | -6,46 | -6,33

Norethindrone | Top (%) | 96,14 | 8,44 (27) | 92,80 | 99,48

Bottom (%) | 2,38 | 5,02 (27) | 0,40 | 4,37

Hill Slope | -1,41 | 0,32 (27) | -1,53 | -1,28

LogIC50(M) | -5,73 | 0,27 (27) | -5,84 | -5,62

10.

See paragraphs 17 and 18 and Table 2 in “ hrER BINDING ASSAY COMPONENTS” of this test method. Each assay (saturation and competitive binding) should consist of three independent runs (i.e. with fresh dilutions of receptor, chemicals, and reagents) on different days, and each run should contain three replicates.

11.

The concentration of active receptor varies slightly by batch and storage conditions. For this reason, the concentration of active receptor as received from the supplier should be determined. This will yield the appropriate concentration of active receptor at the time of the run.

12.

Under conditions corresponding to competitive binding (i.e. 1 nM [3H]-estradiol), nominal concentrations of 0,25, 0,5, 0,75, and 1 nM receptor should be incubated in the absence (total binding) and presence (non-specific binding) of 1 μM unlabelled estradiol. Specific binding, calculated as the difference of total and non-specific binding, is plotted against the nominal receptor concentration. The concentration of receptor that gives specific binding values corresponding to 20 % of added radiolabel is related to the corresponding nominal receptor concentration, and this receptor concentration should be used for saturation and competitive binding experiments. Frequently, a final hrER concentration of 0,5 nM will comply with this condition.

13.

If the 20 % criterion repeatedly cannot be met, the experimental set up should be checked for potential errors. Failure to achieve the 20 % criterion may indicate that there is very little active receptor in the recombinant batch, and the use of another receptor batch should then be considered.

14.

Eight increasing concentrations of [3H]17β-estradiol should be evaluated in triplicate, under the following three conditions (see Table 2):

In the absence of unlabelled 17β-estradiol and presence of ER. This is the determination of total binding by measure of the radioactivity in the wells that have only [3H]17β-estradiol.

In the presence of a 1000- fold excess concentration of unlabelled 17β-estradiol over labelled 17β-estradiol and presence of ER. The intent of this condition is to saturate the active binding sites with unlabelled 17β-estradiol, and by measuring the radioactivity in the wells, determine the non-specific binding. Any remaining hot estradiol that can bind to the receptor is considered to be binding at a non-specific site as the cold estradiol should be at such a high concentration that it is bound to all of the available specific sites on the receptor.

In the absence of unlabelled 17β-estradiol and absence of ER (determination of total radioactivity)

15.

Dilutions of [3H]-17β-estradiol should be prepared by adding assay buffer to a 12 nM stock solution of [3H]-17β-estradiol to obtain concentrations initially ranging from 0,12nM to 12 nM. By adding 40 μl of these solutions to the respective assay wells of a 96-well microtiter plate (in a final volume of 160 μl), the final assay concentrations, ranging from 0,03 to 3,0 nM, will be obtained. Preparation of assay buffer, [3H]-17β-estradiol stock solution and dilutions and determination of the concentrations are described in depth in the FW protocol (2).

16.

Dilutions of ethanolic 17β-estradiol solutions should be prepared by adding assay buffer to achieve eight increasing concentrations initially ranging from 0,06 μM to 6 μM. By adding 80 μl of these solutions to the respective assay wells of a 96-well microtiter plate (in a final volume of 160 μl), the final assay concentrations, ranging from 0,03μM to 3μM, will be obtained. The final concentration of unlabelled 17β-estradiol in the individual non-specific binding assay wells should be 1000-fold of the labelled [3H]-17β- estradiol concentration. Preparation of unlabelled 17β-estradiol dilutions is described in depth in the FW protocol (2).

17.

The nominal concentration of receptor that gives specific binding of 20±5 % should be used (see paragraphs 12-13). The hrERα solution should be prepared immediately prior to use.

18.

The 96-well microtiter plates are prepared as illustrated in Table 2, with 3 replicates per concentration. Example of plate concentration and volume assignment of [3H]-17β-estradiol, unlabelled 17β-estradiol, buffer and receptor are provided in Appendix 2.2.

[3H] E2[3H]-17β-estradiol

ERestrogen receptor

E2unlabelled 17β-estradiol

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |

A | 0,03 nM [3H] E2 + ER | 0,06 nM [3H] E2 + ER | 0,08 nM [3H] E2 + ER | 0,10 nM [3H] E2 + ER | Total Binding (Solvent)

B | 0,30 nM [3H] E2 + ER | 0,60 nM [3H] E2 + ER | 1,0 nM [3H] E2 + ER | 3,0 nM [3H] E2 + ER

C | | | | |

D | 0,03 nM [3H] E2 + ER + 0,03 μM E2 | 0,06 nM [3H] E2 + ER + 0,06 μM E2 | 0,08 nM [3H] E2 + ER + 0,08 μM E2 | 0,10 nM [3H] E2 + ER+ 0,10 μM E2 | Non- Specific Binding

E | 0,30 nM [3H] E2 + ER + 0,30 μM E2 | 0,60 nM [3H] E2 + ER + 0,60 μM E2 | 1,0 nM [3H] E2 + ER+ 1,0 μM E2 | 3,0 nM [3H] E2 + ER +3,0 μM E2

F | | | | |

G | | | | |

H | | | |

19.

Assay microtiter plates should be incubated at 2o to 8oC for 16 to 20 hours and placed on a rotator during the incubation period.

20.

[3H]-17β-Estradiol bound to hrERα should be separated from free [3H]-17β-Estradiol by adding 80 μl of cold DCC suspension to each well, shaking the microtiter plates for 10 minutes and centrifugating for 10 minutes at about 2500 RPM. To minimise dissociation of bound [3H]-17β-estradiol from the hrERα during this process, it is extremely important that the buffers and assay wells be kept between 2 and 8oC and that each step be conducted quickly. A shaker for microtiter plates is necessary to process plates efficiently and quickly.

21.

50 μl of supernatant containing the hrERα-bound [3H]-17β-estradiol should then be taken with extreme care, to avoid any contamination of the wells by touching DCC, and should be placed on a second microtiter plate.

22.

200 μl of scintillation fluid, capable of converting the kinetic energy of nuclear emissions into light energy, should then be added to each well (A1-B12 and D1 to E12). Wells G1-H12 (identified as total dpms) represent serial dilutions of the [3H]-17β-estradiol (40 μl) that should be delivered directly into the scintillation fluid in the wells of the measurement plate as indicated in Table 3, i.e. these wells contain only 200 μl of scintillation fluid and the appropriate dilution of [3H]-17β-estradiol. These measures demonstrate how much [3H]-17β-estradiol in dpms was added to each set of wells for the total binding and non-specific binding.

[3H] E2[3H]-17β-estradiol

ERestrogen receptor

E2unlabelled 17β-estradiol

dpmsdisintegrations per minute

[The hot serial dilutions of [3H]-labelled estradiol here should be directly added into 200 μl of scintillation fluid in wells G1 – H12.]

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |

A | 0,03 nM [3H] E2 + ER | 0,06 nM [3H] E2 + ER | 0,08 nM [3H] E2 + ER | 0,10 nM [3 H] E2 + ER | Total Binding (Solvent)

B | 0,30 nM [3H] E2 + ER | 0,60 nM [3H] E2 + ER | 1,0 nM [3H] E2 + ER | 3,0 nM [3H] E2 + ER

C | | | | |

D | 0,03 nM [3H] E2 + ER + 0,03 μM E2 | 0,06 nM [3H] E2 + ER + 0,06 μM E2 | 0,08 nM [3H] E2 + ER + 0,08 μM E2 | 0,10 nM [3H] E2 + ER+ 0,10 μM E2 | Non- Specific Binding

E | 0,30 nM [3H] E2 + ER + 0,30 μM E2 | 0,60 nM [3H] E2 + ER + 0,60 μM E2 | 1,0 nM [3H] E2 + ER+ 1,0 μM E2 | 3,0 nM [3H] E2 + ER +3,0 μM E2

F | | | | |

G | 0,03 nM [3H] E2(total dpms) | 0,06 nM [3H] E2 | 0,08 nM [3H] E2 | 0,10 nM [3H] E2 | Total dpms

H | 0,30 nM [3H] E2 | 0,60 nM [3H] E2 | 1,0 nM [3H] E2 | 3,0 nM [3H] E2

23.

Measurement should start with a delay of at least 2 hours and counting time should be 40 minutes per well. A microtiter plate scintillation counter should be used for determination of dpm/well with quench correction. Alternatively, if a scintillation counter for a microtiter plate is not available, samples may be measured in a conventional counter. Under these conditions, a reduction of counting time may be considered.

24.

The competitive binding assay measures the binding of a single concentration of [3H]-17β- estradiol in the presence of increasing concentrations of a test chemical. Three concurrent replicates should be used at each concentration within one run. In addition, three non-concurrent runs should be performed for each chemical tested. The assay should be set up in one or more 96-well microtiter plates

25.

When performing the assay, concurrent solvent and controls (i.e. reference estrogen, weak binder, and non-binder) should be included in each experiment. Full concentration curves for the reference estrogen and controls (i.e. weak binder and non-binder) should be used in one plate during each run. All other plates should contain (i) a high- (maximum displacement) and medium- (approximately the IC50) concentration each of E2 and weak binder in triplicate; (ii) solvent control and non-specific binding, each at least in triplicate. Procedures for the preparation of assay buffer, controls, [3H]-17β-estradiol, hrERα and test chemical solutions are described in Reference 2 (Annex K, see FW Assay Protocol).

26.

The solvent control indicates that the solvent does not interact with the test system and also measures total binding (TB). Ethanol is the preferred solvent. Alternatively, if the highest concentration of the test chemical is not soluble in ethanol, DMSO may be used. The concentration of ethanol or DMSO, if used, in the final assay wells is 1,5 % and may not exceed 2 %.

27.

The buffer control (BC) should contain neither solvent nor test chemical, but all of the other components of the assay. The results of the buffer control are compared to the solvent control to verify that the solvent used does not affect the assay system.

28.

17β-estradiol (CAS 50-28-2) is the endogenous ligand and binds with high affinity to the ER, alpha subtype. A standard curve using unlabelled 17β-estradiol should be prepared for each hrERα competitive binding assay, to allow for an assessment of variability when conducting the assay over time within the same laboratory. Eight solutions of unlabelled 17β-estradiol should be prepared in ethanol, with concentrations in the assay wells ranging from 100 nM – 10 pM (-7[logM] to -11[logM]), spaced as follows: (-7[logM], -8[logM], -8.5[logM], -9[logM], - 9,5[logM], -10[logM], -11[logM]). The highest concentration of unlabelled 17β-estradiol (1 μM) also serves as the non-specific binding indicator. This concentration is distinguished by the label “NSB” in Table 4 even though it is also part of the standard curve.

29.

A weak binder (norethynodrel (CAS68-23-5) or norethindrone (CAS 68-22-4)) should be included to demonstrate the sensitivity of each experiment and to allow an assessment of variability when conducting the assay over time. Eight solutions of the weak binder should be prepared in ethanol, with concentrations in the assay wells ranging from 3 nM to 30 μM (-8.5[logM] to -4.5[logM]), spaced as follows: -4.5[logM], -5[logM], -5.5[logM], -6[logM], -6.5[logM], -7[logM],-7.5[logM], -8.5[logM].

30.

Octyltriethoxysilane (OTES, CAS 2943-75-1) should be used as the negative control (non-binder). It provides assurance that the assay as run, will detect when test chemicals do not bind to the hrERα. Eight solutions of the non-binder should be prepared in ethanol, with concentrations in the assay wells ranging from 0,1nM to 1000 μM (-10[logM] to -3[logM]), in log increments. Di-n-butyl phtalate (DBP) can be used as an alternate control non-binder. Its maximum solubility has been shown to be -4[logM].

31.

The amount of receptor that gives specific binding of 20±5 % of 1 nM radioligand should be used (see paragraphs 12-13 of Appendix 2). The hrERα solution should be prepared immediately prior to use.

32.

The concentration of [3H]-17β-estradiol in the assay wells should be of 1,0 nM.

33.

In the first instance, it is necessary to conduct a solubility test to determine the limit of solubility for each test chemical and to identify the appropriate concentration range to use when conducting the test protocol. The limit of solubility of each test chemical is to be initially determined in the solvent and further confirmed under assay conditions. The final concentration tested in the assay should not exceed 1 mM. Range finder testing consists of a solvent control along with 8 log serial dilutions, starting at the maximum acceptable concentration (e.g. 1 mM or lower, based upon the limit of solubility), and the presence of cloudiness or precipitate noted (see also paragraph 35). The test chemical should be tested using 8 log concentration spaced curves as defined by the preceding range finding test. Concentrations in the second and third experiments should be adjusted as appropriate to better characterise the concentration-response curve.

34.

Dilutions of the test chemical should be prepared in the appropriate solvent (see paragraph 26 of Appendix 2). If the highest concentration of the test chemical is not soluble in either ethanol or DMSO, and adding more solvent would cause the solvent concentration in the final tube to be greater than the acceptable limit, the highest concentration may be reduced to the next lower concentration. In this case, an additional concentration may be added at the low end of the concentration series. Other concentrations in the series should remain unchanged.

35.

The test chemical solutions should be closely monitored when added to the assay well, as the test chemical may precipitate upon addition to the assay well. The data for all wells that contain precipitate should be excluded from curve-fitting, and the reason for exclusion of the data noted.

36.

If there is prior existing information from other sources that provide a log(IC50) of a test chemical, it may be appropriate to geometrically space the dilutions (i.e. 0,5 log units around the expected log(IC50). The final result should reflect sufficient spread of concentrations on either side of the log(IC50), including the “top” and “bottom”, such that the binding curve can be adequately characterised.

37.

Labelled microtiter plates should be prepared considering sextuple incubations with codes for the solvent control, the highest concentration of the reference estrogen which also serves as the non-specific binding (NSB) indicator, and the buffer control and considering triplicate incubations with codes for each of the eight concentrations of the non-binding control (octyltriethoxysilane), the 7 lower concentrations for the reference estrogen, the eight concentrations dose levels of the weak binder, and the 8 concentrations of each test chemical (TC). An example layout of the plate diagram for the full concentration curves for the reference estrogen and control is given below in Table 4. Additional microtiter plates are used for the test chemicals and should include plate controls, i.e. 1) a high- (maximum displacement) and medium- (approximately the IC50) concentration each of E2 and weak binder in triplicate; 2) solvent control and non-specific binding, each in sextuple (Table 5). An example of a competitive assay microtiter plate layout worksheet using three unknown test chemicals is provided in Appendix 2.3. The concentrations indicated in Tables 4 and 5 are the final concentrations of the assay. The maximum concentration for E2 should be 1×10–7 M and for the weak binder, the highest concentration used for the weak binder on plate 1 should be used. The IC50 concentration has to be determined by the laboratory based on their historical control database. It is expected that this value would be similar to that observed in the validation studies (see Table 1).

In this example, the weak binder is norethinodrel (NE)

[real blank, well not used] [blank not used during the incubation, but used to confirm the total radioactivity added.]

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12

A | TB (Solvent only) | TB (Solvent only) | NSB | NSB

B | E2 (1×10-7) | E2 (1×10-8) | E2 (1×10-8,5) | E2 (1×10-9)

C | E2 (1×10-9,5) | E2 (1×10-10) | E2 (1×10-11) | Blank

D | NE (1×10-4,5) | NE (1×10-5) | NE (1×10-5,5) | NE (1×10-6)

E | NE (1×10-6,5) | NE (1×10-7) | NE (1×10-7,5) | NE (1×10-8,5)

This article is long: the rest is at the official publication.